Physician profile
Melissa Baker
NPI 1649439993
$832.83
in general payments reported to CMS, 2019-2025
14 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.20 · 2022: $114 · 2023: $145 · 2024: $146 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.31 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $169.38 | 2023-2025 | Vanflyta, Enhertu |
| Sanofi-Aventis U.S. LLC | $153.79 | 2022-2025 | |
| Astellas Pharma US INC | $119.10 | 2024-2025 | Cresemba, Xospata, Vyloy |
| Merck Sharp & Dohme LLC | $108.16 | 2023-2025 | Prevymis, Keytruda |
| Abbvie INC. | $60.25 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $44.04 | 2023-2024 | Imfinzi, Lynparza, Calquence |
| Janssen Biotech, INC. | $34.01 | 2022-2023 | Rybrevant, Erleada |
| Immunocore Limited | $33.41 | 2024-2025 | Kimmtrak |
| Invivyd INC | $31.99 | 2025 | Pemgarda |
| Legend Biotech USA INC. | $18.14 | 2025 | Carvykti |
| Taiho Oncology, INC. | $16.95 | 2024 | |
| Emd Serono, INC. | $16.82 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $13.59 | 2023 | Imbruvica |
| Incyte Corporation | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.